FAST NEWS: HutchMed, AstraZeneca Launch Phase III Trials for Renal Cancer Joint Drug Treatment
The latest: HutchMed (China) Ltd. (0013.HK; HCM.US) announced that it and British drug firm AstraZeneca (AZN.L) have launched phase III global trials for a combination therapy combining the drugs Savolitinib…
Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO
Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points: • Hutchmed announces new approvals…